The British Journal of Rheumatology, Vol 36, 535-540, Copyright © 1997 by British Society for Rheumatology
C Bologna, P Viu, MC Picot, C Jorgensen and J Sany
A total of 453 rheumatoid arthritis (RA) patients were followed up for 35.2
+/- 27.9 months (range 3-106). The clinical parameters decreased
significantly after 6 months. Twenty-eight patients were in remission
(6.4%). Rheumatoid factor (RF) positivity was less common in the group of
patients in remission, with a higher frequency of visits and methotrexate
(MTX) onset after 65 yr. There was a significant degradation of
radiographic lesions (n = 60). A total of 101 patients (23.1%) stopped MTX,
for toxicity (n = 61) and failure (n = 20). The onset of MTX after 65 yr, a
low number of visits and the occurrence of side-effects were predictive of
MTX withdrawal. A total of 259 patients (59.3%) had side-effects. A
Ritchie's index < or = 10, a lower polymorphonuclear cell count and the
absence of RF were predictive of side-effects. The probability of being on
MTX at 5 yr was 73%. This study confirms the high efficacy of MTX in RA.
ORIGINAL PAPERS
Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study
Service d'Immuno-Rhumatologie, CHU Lapeyronie, Montpellier, France.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. J. Edwards, N. K. Arden, D. Fisher, J. C. Saperia, I. Reading, T. P. Van Staa, and C. Cooper The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database Rheumatology, November 1, 2005; 44(11): 1394 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Cronstein Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis Pharmacol. Rev., June 1, 2005; 57(2): 163 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Yarilin, J. Valiando, and D. N. Posnett A Mouse Herpesvirus Induces Relapse of Experimental Autoimmune Arthritis by Infection of the Inflammatory Target Tissue J. Immunol., October 15, 2004; 173(8): 5238 - 5246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Hoekstra, A E van Ede, C J Haagsma, M A F J van de Laar, T W J Huizinga, M W M Kruijsen, and R F J M Laan Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis Ann Rheum Dis, May 1, 2003; 62(5): 423 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. M. van Jaarsveld, Z. N. Jahangier, J. W. G. Jacobs, A. A. M. Blaauw, G. A. van Albada-Kuipers, E. J. ter Borg, H. L. M. Brus, Y. Schenk, M. J. van der Veen, and J. W. J. Bijlsma Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis Rheumatology, December 1, 2000; 39(12): 1374 - 1382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Sokka and P Hannonen Utility of disease modifying antirheumatic drugs in "sawtooth" strategy. A prospective study of early rheumatoid arthritis patients up to 15 years Ann Rheum Dis, October 1, 1999; 58(10): 618 - 622. [Abstract] [Full Text]
|
|